In a recently revealed email, the DEA is looking to consider Delta-8 THC products federally illegal if they are synthesized from CBD.
The Drug Enforcement Administration (DEA) is pondering how to handle Delta-8 tetrahydrocannabinol (THC) products. An attorney recently discovered an email from a top official that discussed the DEA’s views on Delta-8 THC (1). The email mentioned that the agency is against Delta-8 THC when it is synthesized from cannabidiol (CBD) and consider it federally illegal.
Delta-8 THC has exploded in popularity in the cannabis industry. It has been considered to be an intoxicating cannabinoid because if its naturally extracted derivatives similar to CBD which has led it to being the focus of several lawsuits battling state policies that have banned it. Shane Pennington, an attorney, previously posted on his Substack “On Drugs” that while he was looking over the various lawasuits, he discovered a 2021 letter from DEA Drug & Chemical Evaluation Section Chief Terrence Boos that mentioned the DEA’s interpretation of the cannabinoid.
“Arriving at delta-8-THC by a chemical reaction starting from CBD makes the delta-8-THC synthetic and therefore, not exempted by the [Agriculture Improvement Act],” Boos wrote, referring back to the 2018 Farm Bill, that federally legalized hemp (1). “Any quantity of delta-8-THC obtained by chemical means is a controlled substance.”
The DEA held their 2023 Supply Chain Conference in May 2023 and stated that synthetic cannabinoids were banned. Boos added that the agency is working on establishing a final ruling on the cannabinoids to formally clarify the policy which was recommended by the US Department of Health and Human Services (1).
In February 2023, Boos informed an attorney that minor cannabinoids delta-8 THC-O and delta-9 THC-O were illegal due to the fact that they are only able to be produced synthetically and not naturally.
Even with the DEA’s opinions on synthetic cannabinoids, there still exists a strong market for products like delta-8 THC. Various states have followed by banning the cannabinoid, among others, in their states. The Food and Drug Administration has mostly sent warning letters to companies that were labeled ‘problematic’. Without a formal policy, there is no enforcement or regulation of delta-8 THC and other cannabinoid products.
Reference
Empowering Women in Cannabis: Susan Audino, PhD, on Inclusivity, Integrity, and Industry Challenges
December 11th 2024Founder of S. A. Audino & Associates, LLC, Susan Audino, PhD, recently co-founded Saturn Scientific, LLC, a collaboration of five experienced individuals providing unbiased evaluations on the data and science for stakeholders in the cannabis industry. In this interview with Cannabis Science and Technology, Dr. Audino shares her unexpected path into analytical science and the cannabis industry as well as the obstacles she’s faced throughout her career. She highlights the gender bias she’s observed, such as unequal recognition of credentials and workplace challenges, while advocating for inclusivity and mentorship to empower women in science. Additionally, Dr. Audino recounts her experiences of navigating the male-dominated cannabis space, pushing for transparency, collaboration, and integrity in laboratory practices. Ultimately, Audino believes fostering mutual respect and knowledge-sharing is vital for the industry’s growth and resilience.
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
Ep 23, Part III: Accreditation in the Cannabis Industry with Susan Audino
October 24th 2024In Part III of this episode, host Evan Friedmann is joined by Susan Audino, PhD, founder of S.A. Audino & Associates, LLC, and co-founder of Saturn Scientific, LLC, to examine the complexities of sampling in the cannabis industry, emphasizing the need for proper sampling plans, and methods.